Riliprubart

On July 25, Sanofi announced details of its latest round of pipeline adjustments and financial performance. As part of its ongoing efforts to optimize its product development portfolio, the company decided to streamline its product pipeline, withdrew further development work for two projects, and implemented slower clinical development schedules for three other projects. Specifically, Sanofi has decided to terminate its Phase II study of the complement C1s monoclonal antibody riliprubart against cold agglutinin disease, as well as the Phase I clinical trial of SP0273, a quadrivalent influenza mRNA vaccine candidate. These two decisions demonstrate the seriousness with which Sanofi evaluates project prospects and allocates resources. In addition, Sanofi has carefully adjusted its clinical development program for three other assets, including FGFR3 antibody SAR442501 (for the treatment of achondroplasia), TGF-β antibody SAR439459 (for the treatment of osteogenesis implasia), and PH4H-targeted gene therapy SAR444836 for phenylketonuria. These changes are designed to ensure that the company's investment in research and development is more accurately focused on the most promising projects. Despite these pipeline changes, Sanofi's financial performance remains solid. In the first half of 2024, the company's total revenue reached 21.209 billion euros, an increase of 5.1% year-on-year. Despite the decline in net profit, which fell by 34.5% to €2.246 billion, the result still reflects the company's solid ability to operate in a complex market environment. In terms of geographical distribution, Sanofi performed particularly well in the US market, achieving 13.4% revenue growth; The European market was somewhat challenging, with revenue down 3.2%. The Chinese market maintained a growth rate of 2.8%, continuing to consolidate Sanofi's leading position in the region. In terms of business segments, Sanofi also showed a balanced development trend. The pharmaceutical business achieved a 9.6 percent increase, vaccines also achieved a small 0.3 percent increase, and consumer health business achieved a significant 9.2 percent increase. In particular, Dupixent, the company's flagship product, continued to play its central role, with sales of €6.138 billion in the first half of the year, up 27.1% year-on-year, contributing to an important revenue stream for the company. Sanofi has once again demonstrated its leadership position in the global pharmaceutical industry through a smart pipeline strategy and solid financial performance. The company not only demonstrated strong flexibility and adaptability, but also achieved remarkable results in optimizing operations and resource allocation.

June 28, 2024 -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. Two poster presentations at EAN will highlight preclinical and in vitro data describing the potentially differentiated profile of DNTH103 in disease models of generalized Myasthenia Gravis (gMG) and Chronic Demyelinating Polyneuropathy (CIDP), in addition to head-to-head affinity and pharmacodynamic (PD) potency data for DNTH103 compared to Riliprubart. Dianthus Presentations at EAN: June 29, 2024, 14:10 EEST DNTH103, a Potentially Safer and More Convenient Novel Therapy for Generalised Myasthenia Gravis Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118 June 30, 2024, 14:25 EEST DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243 These posters will be made available in the Scientific Publications section of the Dianthus website after they are presented. “Currently, therapies for patients with generalized Myasthenia Gravis (gMG) are limited to C5 inhibitors or FcRn inhibitors that can be burdensome for patients and caregivers, and the C5 complement inhibitors available today have an increased risk for serious bacterial infections. Similarly, treatment options for patients with CIDP have traditionally been limited to intravenous or subcutaneous infusions of Ig,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “We aim to demonstrate that DNTH103 may become a best-in-class classical complement pathway inhibitor with infrequent self-administration that provides effective and consistent control of symptoms for people living with neuromuscular conditions, without inhibiting the alternative and lectin pathways that are critical in the defense against infection.” DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. DNTH103 is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, self-administered injection dosed as infrequently as once every two weeks. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis in 1Q’24, regulatory clearance for Multifocal Motor Neuropathy in 2Q’24, and planned initiation of a Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy in 2H’24. Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. The content above comes from the network. if any infringement, please contact us to modify.